ArriVent BioPharma (ArriVent BioPharma) Total Long-Term Assets : $0.36 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. ArriVent BioPharma's Total Long-Term Assets for the quarter that ended in Mar. 2024 was $0.36 Mil.

ArriVent BioPharma Total Long-Term Assets Historical Data

The historical data trend for ArriVent BioPharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Total Long-Term Assets Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Total Long-Term Assets

0.09

0.21

3.13

ArriVent BioPharma Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Long-Term Assets	Get a 7-Day Free Trial				-	0.16	2.01	3.13	0.36

ArriVent BioPharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

ArriVent BioPharma Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma (ArriVent BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus

ArriVent Appoints Kristine Peterson to its Board of Directors

By Marketwired • 04-22-2024